Drug Patents owned by Siga Technologies

1. List of Tpoxx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8124643 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US9339466 SIGA TECHNOLOGIES Polymorphic forms of ST-246 and methods of preparation
Mar, 2031

(8 years from now)

CN101702904A SIGA TECHNOLOGIES Chemicals, Compositions, And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Aug, 2015

(7 years ago)

EP1638938A2 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

EP1638938A4 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

EP1638938B1 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802714 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US8530509 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US8039504 SIGA TECHNOLOGIES Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jul, 2027

(4 years from now)

US9233097 SIGA TECHNOLOGIES ST-246 liquid formulations
Aug, 2031

(8 years from now)

US9907859 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(8 years from now)

US10576165 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(8 years from now)

US7737168 SIGA TECHNOLOGIES Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 13, 2023
Orphan Drug Exclusivity (ODE) Jul 13, 2025

Drugs and Companies using TECOVIRIMAT ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 13 July, 2018

Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg; Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in